Use of soluble TREM2 as non-invasive biomarker for NASH

Jonas Heilskov Graversen; Vineesh Indira Chandran; Søren Kragh Moestrup; Maria Kløjgaard Skytthe; Aleksander Krag; Charlotte Wernberg; MM Lauridsen

Use of soluble TREM2 as non-invasive biomarker for NASH

Jonas Heilskov Graversen (Inventor), Vineesh Indira Chandran (Inventor), Søren Kragh Moestrup (Inventor), Maria Kløjgaard Skytthe (Inventor), Aleksander Krag (Inventor), Charlotte Wernberg (Inventor), MM Lauridsen (Inventor)

Research output: Patent

Abstract

Reliable non-invasive biomarkers are an unmet clinical need for the diagnosis of NASH patients. Herein we identify soluble TREM2 as a non-invasive plasma biomarker to diagnose NASH in obese patients and provides evidence for sTREM2 as an accurate predictor of advanced hepatic inflammation, ballooning, and fibrosis.

Original language	English
IPC	G01N33/68
Patent number	WO2022248363 (A1)
Country/Territory	Denmark
Priority date	28/05/2021
Priority number	EP20210176575
Publication status	Published - 1. Dec 2022

Cite this

@misc{7b62a7e8648049fc85965b30d647111b,

title = "Use of soluble TREM2 as non-invasive biomarker for NASH",

abstract = "Reliable non-invasive biomarkers are an unmet clinical need for the diagnosis of NASH patients. Herein we identify soluble TREM2 as a non-invasive plasma biomarker to diagnose NASH in obese patients and provides evidence for sTREM2 as an accurate predictor of advanced hepatic inflammation, ballooning, and fibrosis.",

author = "Graversen, {Jonas Heilskov} and Chandran, {Vineesh Indira} and Moestrup, {S{\o}ren Kragh} and Skytthe, {Maria Kl{\o}jgaard} and Aleksander Krag and Charlotte Wernberg and MM Lauridsen",

year = "2022",

month = dec,

day = "1",

language = "English",

type = "Patent",

note = "WO2022248363 (A1) ; G01N33/68",

}

TY - PAT

T1 - Use of soluble TREM2 as non-invasive biomarker for NASH

AU - Graversen, Jonas Heilskov

AU - Chandran, Vineesh Indira

AU - Moestrup, Søren Kragh

AU - Skytthe, Maria Kløjgaard

AU - Krag, Aleksander

AU - Wernberg, Charlotte

AU - Lauridsen, MM

PY - 2022/12/1

Y1 - 2022/12/1

N2 - Reliable non-invasive biomarkers are an unmet clinical need for the diagnosis of NASH patients. Herein we identify soluble TREM2 as a non-invasive plasma biomarker to diagnose NASH in obese patients and provides evidence for sTREM2 as an accurate predictor of advanced hepatic inflammation, ballooning, and fibrosis.

AB - Reliable non-invasive biomarkers are an unmet clinical need for the diagnosis of NASH patients. Herein we identify soluble TREM2 as a non-invasive plasma biomarker to diagnose NASH in obese patients and provides evidence for sTREM2 as an accurate predictor of advanced hepatic inflammation, ballooning, and fibrosis.

M3 - Patent

M1 - WO2022248363 (A1)

ER -

Use of soluble TREM2 as non-invasive biomarker for NASH

Abstract

Fingerprint

Cite this